RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo

Oncotarget

Volumn 5, Issue 22, 2014, Pages 11567-11582

  Wang, Wei ^a   Cheng, Jianwen ^b   Qin, Jiang Jiang ^a   Voruganti, Sukesh ^a   Nag, Subhasree ^a   Fan, Jia ^b   Gao, Qiang ^b   Zhang, Ruiwen ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Combination therapy; HCC; Prognosis; RYBP

Indexed keywords

BINDING PROTEIN; CISPLATIN; RING 1 AND YY1 BINDING PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; RYBP PROTEIN, HUMAN; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; PREDICTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; ADENOVIRIDAE; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; DISEASE COURSE; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; LIVER NEOPLASMS; METABOLISM; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NUDE MOUSE; PROGNOSIS; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICE; MICE, NUDE; MULTIVARIATE ANALYSIS; NEOPLASM TRANSPLANTATION; PROGNOSIS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84917696389     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30.
2. El-Serag HB. Hepatocellular Carcinoma. N Engl J Med. 2011; 365(12):1118-1127.
3. Wang K. Molecular mechanisms of hepatic apoptosis. Cell Death Dis. 2014; 5:e996.
4. Sparmann A, Van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006; 6(11):846-856.
5. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010; 7(3):299-313.
6. Richly H, Aloia L, Di Croce L. Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis. 2011; 2:e204.
7. Garcia E, Marcos-Gutierrez C, del Mar Lorente M, Moreno JC, Vidal M. RYBP, a new repressor protein that interacts with components of the mammalian Polycomb complex, and with the transcription factor YY1. EMBO J. 1999; 18(12):3404-3418.
8. Trimarchi JM, Fairchild B, Wen J, Lees JA. The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc Natl Acad Sci U S A. 2001; 98(4):1519-1524.
9. Novak RL, Phillips AC. Adenoviral-mediated Rybp expression promotes tumor cell-specific apoptosis. Cancer Gene Ther. 2008; 15(11):713-722.
10. Gonzalez I, Busturia A. High levels of dRYBP induce apoptosis in Drosophila imaginal cells through the activation of reaper and the requirement of trithorax, dredd and dFADD. Cell Res. 2009; 19(6):747-757.
11. Danen-van Oorschot AA, Voskamp P, Seelen MC, Van Miltenburg MH, Bolk MW, Tait SW, et al. Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. Cell Death Differ. 2004; 11(5):564-573.
12. Zheng L, Schickling O, Peter ME, Lenardo MJ. The death effector domain-associated factor plays distinct regulatory roles in the nucleus and cytoplasm. J Biol Chem. 2001; 276(34):31945-31952.
13. McGarry LC, Winnie JN, Ozanne BW. Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. Oncogene. 2004; 23(31):5284-5292.
14. Zhou L, Wang L, Lu L, Jiang P, Sun H, Wang H. A novel target of microRNA-29, Ring1 and YY1-binding protein (Rybp), negatively regulates skeletal myogenesis. J Biol Chem. 2012; 287(30):25255-25265.
15. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 2006; 66(3):1277-1281.
16. Chen D, Zhang J, Li M, Rayburn ER, Wang H, Zhang R. RYBP stabilizes p53 by modulating MDM2. EMBO Rep. 2009; 10(2):166-172.
17. Fang B, Roth JA. The role of gene therapy in combined modality treatment strategies for cancer. Curr Opin Mol Ther. 2003; 5(5):475-482.
18. Brown KS. Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases. Semin Intervent Radiol. 2006; 23(1):99-108.
19. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22.
20. Lando M, Holden M, Bergersen LC, Svendsrud DH, Stokke T, Sundfor K, et al. Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet. 2009; 5:e1000719.
21. Martin-Perez D, Piris MA, Sanchez-Beato M. Polycomb proteins in hematologic malignancies. Blood. 2010; 116(25):5465-5475.
22. Stanton SE, Blanck JK, Locker J, Schreiber-Agus N. Rybp interacts with Hippi and enhances Hippi-mediated apoptosis. Apoptosis. 2007; 12(12):2197-2206.
23. Pirity MK, Locker J, Schreiber-Agus N. Rybp/DEDAF is required for early postimplantation and for central nervous system development. Mol Cell Biol. 2005; 25(16):7193-7202.
24. Franziska VZ, Gudrun Z, Michaela P, Doris S, Christoph K, Mara H,et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Uture Oncol. 2009; 5(8):1169-1179.
25. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009; 119(6):1429-1437.
26. Marin J, Castaño B, Martinez-Becerra P, Rosales R, Monte M. Chemotherapy in the treatment of primary liver tumours. Cancer Therapy. 2008; 6:711-728.
27. Ishikawa T. Future perspectives on the treatment of hepatocellular carcinoma with cisplatin. World of Hepatol. 2009; 1(1):8-16
28. Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011; 3(1):1351-1371.
29. Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 2014; 740C: 364-378.
30. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009; 15(3):971-979.
31. Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, et al. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol. 2001; 7(5):630-636.
32. Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J, et al. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol. 2003; 129(1):43-51.
33. Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc. 2007; 2(5):1236-1247.
34. Wang W, Rayburn ER, Velu SE, Nadkarni DH, Murugesan S, Zhang R. In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res. 2009; 15(10):3511-3518.
35. Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, et al. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice. Gastroenterology. 2014; 147(4):893-902.
36. Wang W, Qin JJ, Voruganti S, Srivenugopal K, Nag S, Patil S, et al. The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Nature Commun. 2014; 5:5086.
37. Zhang X, Zhang L, Xu W, Qian H, Ye S, Zhu W, et al. Experiment therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediatedinterleukin-24 delivery. Curr Cancer Drug Targets. 2013; 13(1):92-102.
38. Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu P, Chen KK, et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology. 2010; 52(2):528-539.
39. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell. 2011; 9(1):50-63.
40. Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 2003; 63(21):7497-7506.
41. Xu WP, Yi M, Li QQ, Zhou WP, Cong WM, Yang Y, et al. Perturbation of MicroRNA-370/Lin-28 homolog A/nuclear factor kappa B regulatory circuit contributes to the development of hepatocellular carcinoma. Hepatology. 2013; 58(6):1977-1991.
42. Yin C, Wang PQ, Xu WP, Yang Y, Zhang Q, Ning BF, et al. Hepatocyte nuclear factor-4a reverses malignancy of hepatocellular carcinoma through regulating miR-134 in the DLK1-DIO3 region. Hepatology. 2013; 58(6):1964-1976.